leisure time -WSS

leisure time

author：fashion 2025-08-25 07:26:16 - browse：1376

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Bristol 'take

WSS

FDA authorizes Novavax’s updated Covid

3 questions for the future of Biden's cancer moonshot

Why age limits for politicians are a terrible idea

Sana to lay off nearly a third of staff, de

Sana to lay off nearly a third of staff, de

Pharma’s losing bet in New Jersey

focus

leisure time

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Moonlake's readout produced a cash windfall. Risks remain

Pharma’s losing bet in New Jersey

How to save PrEP access — and even expand it

Guardant Health colon cancer test endorsed by FDA advisory panel

BioMarin wins approval for gene therapy to treat hemophilia A

Bird flu makes raw milk dangerous to consume, mouse study finds

Continuity nursing helped my family in our darkest PICU moments

AI can decode, harness the power of the humane immune system

focus

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Bristol 'take

What to expect at HLTH 2023, the health care industry conference

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Why we need mandatory labeling of GMO products

explore

hotspot

hotspot

hotspot